DURECT (NASDAQ:DRRX) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of DURECT (NASDAQ:DRRX) in a report issued on Tuesday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Separately, HC Wainwright reiterated a “neutral” rating on shares of DURECT in a research note on Thursday, November 14th.

DURECT Price Performance

NASDAQ:DRRX opened at $0.92 on Tuesday. The company has a market cap of $28.63 million, a P/E ratio of -1.51 and a beta of 1.13. The firm’s fifty day moving average price is $1.34 and its two-hundred day moving average price is $1.37. DURECT has a one year low of $0.48 and a one year high of $1.88.

Institutional Trading of DURECT

Several institutional investors have recently added to or reduced their stakes in DRRX. Richmond Brothers Inc. increased its position in DURECT by 39.5% during the 2nd quarter. Richmond Brothers Inc. now owns 1,072,014 shares of the specialty pharmaceutical company’s stock worth $1,383,000 after buying an additional 303,670 shares during the period. Accredited Investors Inc. bought a new position in DURECT during the second quarter worth about $113,000. Geode Capital Management LLC raised its stake in DURECT by 4.8% in the 3rd quarter. Geode Capital Management LLC now owns 319,905 shares of the specialty pharmaceutical company’s stock worth $429,000 after purchasing an additional 14,658 shares in the last quarter. Finally, International Assets Investment Management LLC boosted its holdings in DURECT by 41.3% in the 2nd quarter. International Assets Investment Management LLC now owns 21,550 shares of the specialty pharmaceutical company’s stock valued at $28,000 after purchasing an additional 6,300 shares during the period. 28.03% of the stock is currently owned by institutional investors.

About DURECT

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.